Schuster D, Schneider G, Ade N, Heim M E
Oncology Center Mannheim, University of Heidelberg.
Onkologie. 1990 Oct;13(5):359-62. doi: 10.1159/000216796.
Experimental results suggest synergistic activity of interferon with different cytotoxic agents, including vinblastine. Both interferon and vinblastine have shown synergistic activity against renal cell carcinoma in the human stem cell assay. In this multicenter phase II study, patients with documented advanced renal cell carcinoma were treated with interferon alpha-2a at a dose of 18 x 10(6) IU i.m. 3 days per week and vinblastine 0.1 mg/kg body weight i.v. every 3 weeks. Combination therapy was given for 6 months except patients with progressive disease. We observed 6/34 (17.6%) partial remissions and 16/34 (47%) no changes. Five out of six responses were seen in pulmonary metastases with a median response duration of 10 months and a median survival for the responders of 17 months. A dose reduction because of interferon toxicity was necessary in 60% of the treated patients. The main side effects were fever and influenza-like symptoms of different intensity in 70% of the patients, which decreased during the treatment periods. This trial demonstrates modest but definite antitumor activity of the combination of interferon alpha-2a/vinblastine. In comparison with single agent therapy we did not observe improved remission rates for the combination treatment.
实验结果表明，干扰素与包括长春碱在内的不同细胞毒性药物具有协同活性。在人类干细胞试验中，干扰素和长春碱均已显示出对肾细胞癌的协同活性。在这项多中心II期研究中，对记录在案的晚期肾细胞癌患者，采用每周3天、每次18×10(6)国际单位的α-2a干扰素肌肉注射，以及每3周静脉注射0.1毫克/千克体重长春碱进行治疗。除疾病进展的患者外，联合治疗持续6个月。我们观察到6/34例（17.6%）部分缓解，16/34例（47%）无变化。6例缓解中有5例出现在肺转移患者中，中位缓解持续时间为10个月，缓解者的中位生存期为17个月。60%接受治疗的患者因干扰素毒性需要降低剂量。70%的患者主要副作用为不同程度的发热和流感样症状，在治疗期间有所减轻。该试验证明了α-2a干扰素/长春碱联合治疗具有适度但确切的抗肿瘤活性。与单药治疗相比，联合治疗并未观察到缓解率提高。
